Alder BioPharmaceuticals, Inc. (ALDR) was a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine and other medical conditions. The company's lead product candidate was eptinezumab, a monoclonal antibody in development for the prevention of chronic migraine and episodic migraine.
In 2019, ALDR was acquired by H. Lundbeck A/S, a global pharmaceutical company specializing in psychiatric and neurological disorders. As part of the acquisition, eptinezumab was integrated into Lundbeck's product portfolio and became the company's first biologic therapy for migraine prevention.
ALDR was founded in 2002 and was headquartered in Bothell, Washington.
Alder BioPharmaceuticals, Inc. (ALDR) was a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine and other medical conditions. The company's lead product candidate was eptinezumab, a monoclonal antibody in development for the prevention of chronic migraine and episodic migraine.